Chouchane A, Brautigam K, Perren A
Pathologie (Heidelb). 2025; 46(2):127-136.
PMID: 39969551
PMC: 11861404.
DOI: 10.1007/s00292-025-01415-z.
Yin L, Wang R, Ma X, Jiang K, Hu Y, Zhao X
Sci Rep. 2025; 15(1):3287.
PMID: 39865119
PMC: 11770191.
DOI: 10.1038/s41598-025-86237-y.
He X, Yang S, Ren J, Wang N, Li M, You Y
Front Oncol. 2024; 14:1480466.
PMID: 39507752
PMC: 11538776.
DOI: 10.3389/fonc.2024.1480466.
Ratnayake G, Shekhda K, Glover T, Al-Obudi Y, Hayes A, Armonis P
J Neuroendocrinol. 2024; 37(1):e13465.
PMID: 39503166
PMC: 11750320.
DOI: 10.1111/jne.13465.
Ebner R, Sheikh G, Brendel M, Ricke J, Cyran C
Eur Radiol. 2024; .
PMID: 39387873
DOI: 10.1007/s00330-024-11095-7.
Portuguese Pancreatic Club Perspective on the Surveillance Strategy for Pancreatic Neuroendocrine Tumours: When and How to Do It?.
Bispo M, Marques S, Fernandes A, Rodrigues-Pinto E, Vilas-Boas F, Rio-Tinto R
GE Port J Gastroenterol. 2024; 31(5):306-313.
PMID: 39360175
PMC: 11444664.
DOI: 10.1159/000535815.
Characteristics, therapy, and outcome of rare functioning pancreatic neuroendocrine neoplasms.
Albers M, Sevcik M, Wiese D, Manoharan J, Rinke A, Jesinghaus M
Sci Rep. 2024; 14(1):18507.
PMID: 39122816
PMC: 11316089.
DOI: 10.1038/s41598-024-68290-1.
Clinical outcomes after endoscopic resection and the risk of lymph node metastasis in rectal neuroendocrine tumors: a single-center retrospective study.
Tie S, Fan M, Zhang J, Yu J, Wu N, Su G
Surg Endosc. 2024; 38(9):5178-5186.
PMID: 39043886
DOI: 10.1007/s00464-024-11088-z.
Emerging Treatment Options for Neuroendocrine Neoplasms of Unknown Primary Origin: Current Evidence and Future Perspectives.
Corti F, Rossi R, Cafaro P, Passarella G, Turla A, Pusceddu S
Cancers (Basel). 2024; 16(11).
PMID: 38893145
PMC: 11171242.
DOI: 10.3390/cancers16112025.
Comparative Study of Ki-67 Labeling Index Quantification by Eye-rolling, Manual Count, and Digital Image Analysis; An Approach with Caution.
Singh A, Narang V, Soni A, Angural K, Jindal S, Garg B
Iran J Pathol. 2024; 19(1):75-80.
PMID: 38864080
PMC: 11164310.
DOI: 10.30699/IJP.2024.2008346.3150.
Co-existing Neuroendocrine Tumors in the Ileum and Pancreas: A Clinico-Pathological Challenge.
Laffi A, Bertuzzi A, Carrara S, Zerbi A, Lania A, Lavezzi E
Endocr Pathol. 2024; 35(3):256-266.
PMID: 38848012
DOI: 10.1007/s12022-024-09814-3.
Portuguese Pancreatic Club Perspectives on Pancreatic Neuroendocrine Neoplasms: Diagnosis and Staging, Associated Genetic Syndromes and Particularities of Their Clinical Approach.
Ferreira-Silva J, Meireles S, Falconi M, Fernandes A, Vilas-Boas F, Bispo M
GE Port J Gastroenterol. 2024; 31(3):153-164.
PMID: 38836119
PMC: 11149993.
DOI: 10.1159/000534641.
[Current WHO classification (2022) of neuroendocrine neoplasms].
Buchstab O, Knosel T
Radiologie (Heidelb). 2024; 64(7):531-535.
PMID: 38622292
DOI: 10.1007/s00117-024-01295-z.
From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms.
Melhorn P, Mazal P, Wolff L, Kretschmer-Chott E, Raderer M, Kiesewetter B
Ther Adv Med Oncol. 2024; 16:17588359241240316.
PMID: 38529270
PMC: 10962050.
DOI: 10.1177/17588359241240316.
Influence of Lymphatic, Microvascular and Perineural Invasion on Oncological Outcome in Patients with Neuroendocrine Tumors of the Small Intestine.
Butz F, Dukaczewska A, Kunze C, Kromer J, Reinhard L, Jann H
Cancers (Basel). 2024; 16(2).
PMID: 38254794
PMC: 10813650.
DOI: 10.3390/cancers16020305.
Evaluation of quality of clinical management of neuroendocrine tumors.
Bloemen H, Kneepkens K, Deraedt K, Ivanova A, Sergeant G, Mebis J
Cancer Innov. 2023; 1(4):305-315.
PMID: 38089084
PMC: 10686178.
DOI: 10.1002/cai2.41.
Inspired by novel radiopharmaceuticals: Rush hour of nuclear medicine.
Liu Y, Ren Y, Cui Y, Liu S, Yang Z, Zhu H
Chin J Cancer Res. 2023; 35(5):470-482.
PMID: 37969954
PMC: 10643344.
DOI: 10.21147/j.issn.1000-9604.2023.05.05.
When is surgery indicated in metastatic small intestine neuroendocrine tumor?.
Draskacheva N, Saljamovski D, Gosic V, Trajkovski G, Ristovski G, Misimi S
J Surg Case Rep. 2023; 2023(10):rjad580.
PMID: 37873052
PMC: 10590655.
DOI: 10.1093/jscr/rjad580.
Myasthenia gravis as initial presentation of a pancreatic neuroendocrine tumor: A case report.
Stingu E, Dobrowolski J, Bombach P, Nann D, Singer S, Horger M
Exp Ther Med. 2023; 26(5):523.
PMID: 37854502
PMC: 10580239.
DOI: 10.3892/etm.2023.12222.
Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial.
Corti F, Brizzi M, Amoroso V, Giuffrida D, Panzuto F, Campana D
BMC Cancer. 2023; 23(1):908.
PMID: 37752423
PMC: 10523723.
DOI: 10.1186/s12885-023-11287-2.
